A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
The FDA has approved Auxilium Pharmaceuticals’ Xiaflex biologic injection for Peyronie’s disease, a deformity of the penis caused by a lump of plaque that results in a curvature of at least 30 degrees.
ZOLL Medical, a manufacturer of medical devices and related software solutions and a wholly owned U.S. subsidiary of Asahi Kasei, has established Asahi Kasei ZOLL Medical Corporation as its Japanese subsidiary effective Nov. 5. The Herald